Align Technology's (ALGN) first-quarter 2012 adjusted EPS of $0.27 surpassed the Zacks Consensus Estimate of $0.22 and the year-ago quarter adjusted EPS of $0.21. Align witnessed balanced sales growth across all its channels, banking on its core product, Invisalign.
Moreover, Cadent's contribution also helped Align to further penetrate the malocclusion market. Align's focus on the international market, especially in Europe, is encouraging. A successful launch of Invisalign G4 is expected to boost the company's revenues further.
Although Align is facing gross margin compression for several quarters, the gradual pick up in patient traffic is expected to add further life to the company's overall performance. Based on the strong growth potential of the company, we upgraded the stock to Outperform.
ALIGN TECH INC (ALGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
New York: Thu 23 May 08:50 am



or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.